ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2026
De-escalation of Medications After Initiation of Elexacaftor-Tezacaftor-Ivacaftor in Children 6 to 11 Years of Age With Cystic Fibrosis.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients With Cystic Fibrosis.Pediatric pulmonology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThe management of cystic fibrosis (CF) requires intensive, chronic medication regimens that can have a high treatment burden and cost. De-escalation of chronic medications for patients with CF aged 12 years and older on elexacaftor-tezacaftor-ivacaftor (ETI) has been evaluated; however, data are lacking for patients aged 6 to 11 years.
methodsThis single-center, retrospective study evaluated the non-inferiority of chronic medication de-escalation following an institutional algorithm in children 6 to 11 years with CF by comparing the difference in percent predicted FEV
resultsForty-one patients were included. The sample's baseline mean ppFEV
conclusionsFollowing the initiation of an institutional medication de-escalation algorithm, the number of chronic medications in children aged 6 to 11 years with CF on ETI was decreased. However, this study was unable to confirm the non-inferiority of chronic medication de-escalation in this younger population with CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.